SUMMARY Microvascular disease is a contributor to persistent pulmonary hypertension in those with chronic thromboembolic pulmonary hypertension (CTEPH). The heterogenous nature of the micro and macrovascular defects motivates the use of personalized computational models, which can predict flow dynamics within multiple generations of the arterial tree and into the microvasculature. Our study uses computational hemodynamics models and Gaussian processes for rapid, subject-specific calibration using retrospective data from a large animal model of CTEPH. Our subject-specific predictions shed light on microvascular dysfunction and arterial wall shear stress changes in CTEPH. Key words: 1D fluid dynamics, gaussian processes, parameter inference, emulation 1 INTRODUCTION Chronic thromboembolic pulmonary hypertension (CTEPH) is a subgroup of pulmonary hypertension (PH) caused by blood clots that lodge in the blood vessels of the lungs.

AI could also have a transformative effect on clinical decision-making through the utilisation of the huge levels of genomic, biomarker, phenotype, behavioural, biographical and clinical data that is generated across the health system. Bayer and Merck & Co provide a perfect example of this. They have developed an AI software system to support clinical decision-making of chronic thromboembolic pulmonary hypertension (CTEPH) – a rare form of pulmonary hypertension. The software helps differentiate patients from those suffering with similar symptoms that are actually a result of asthma and chronic obstructive pulmonary disease (COPD), and therefore diagnose CTEPH more reliably and efficiently. The CTEPH Pattern Recognition Artificial Intelligence obtained FDA Breakthrough Device Designation in December 2018.